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AKAP95 regulates splicing through scaffolding
RNAs and RNA processing factors
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Alternative splicing of pre-mRNAs signiﬁcantly contributes to the complexity of gene
expression in higher organisms, but the regulation of the splice site selection remains
incompletely understood. We have previously demonstrated that a chromatin-associated
protein, AKAP95, has a remarkable activity in enhancing chromatin transcription. In this
study, we show that AKAP95 interacts with many factors involved in transcription and RNA
processing, including selective groups of hnRNP proteins, through its N-terminal region, and
directly regulates pre-mRNA splicing. AKAP95 binds preferentially to proximal intronic
regions on pre-mRNAs in human transcriptome, and this binding requires its zinc-ﬁnger
domains. By selectively coordinating with hnRNP H/F and U proteins, AKAP95 appears to
mainly promote the inclusion of many exons in the genome. AKAP95 also directly interacts
with itself. Taken together, our results establish AKAP95 as a mostly positive regulator of
pre-mRNA splicing and a possible integrator of transcription and splicing regulation.
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ascent messenger RNA (mRNA) precursors (pre-
mRNAs) in eukaryotic cells are subject to extensive
processing, including splicing to remove introns, to
generate mature mRNAs. These processing steps are accom-
plished by coordinated action of many RNA-interacting proteins
and RNAs. Alternative splicing (AS) of pre-mRNA is a major
source of proteomic diversity in metazoans, as over 95% of
human multi-exon pre-mRNAs are processed into two or more
mRNA isoforms1,2, and the frequency of AS correlates with
organism complexity along evolution3,4. AS regulation also plays
crucial roles in diverse biological processes5, and disruption of AS
control can result in human diseases6.
The core splicing signals include the 50 splice site, the 30 splice
site and the branch point sequence, and are primarily recognized
by the basal splicing machinery – the spliceosome. In addition to
the core splicing signals, numerous cis-regulatory elements are
present in exons and introns of pre-mRNAs to serve as splicing
enhancers or silencers7. The functions of the cis-elements are
mediated by a number of trans-acting splicing factors, including
SR and SR-related proteins, heterogeneous nuclear ribonucleo-
proteins (hnRNPs), and other tissue-speciﬁc RNA-binding
proteins8. These factors activate or suppress either splice site
recognition or spliceosome assembly via various mechanisms9,
often in a context-dependent manner10.
hnRNP proteins, including at least 20 proteins named hnRNP
A1 through hnRNP U, are a structurally diverse group of
RNA-binding proteins that participate in many aspects of RNA
processing including constitutive and alternative splice regula-
tion11. Although earlier studies largely point to a repressive role
of hnRNPs in splicing, it is now clear that they both promote and
repress splicing11,12. Some hnRNPs, most notably hnRNP F, H1
and U, have a higher tendency to promote exon inclusion than
exclusion12. Following their direct binding to pre-mRNAs,
hnRNPs can control splice site selection by occluding the
binding of splice-regulatory factors to splice sites or splice
enhancers and by hindering or facilitating the communication
between splice sites. For example, hnRNP A/B and hnRNP
F/H have been shown to engage in homotypic or hetero-
typic interactions and bring different intronic regions into close
proximity, thus ‘looping out’ the in-between RNA sequence13,14.
The inclusion of a cassette exon can be either promoted or
repressed, depending whether the exon is ﬂanking or within the
looped out sequence. A rather similar strategy is apparently
adopted by hnRNP C, which may also bring two splice sites into
close proximity through self-interaction, and thereby promote or
inhibit the inclusion of a cassette exon depending on the exon’s
location relative to the splice sites brought together by hnRNP C
(ref. 15).
In addition to the individual cis- and trans-acting elements, it is
increasingly clear that splicing is dynamically regulated within the
integrated network of gene expression including transcrip-
tion16,17, as most splicing events occur cotranscriptionally.
Several splicing factors have been shown to physically interact
with the basal transcriptional machinery, and the rate of
transcription elongation can play important roles in regulating
the splice site selection17. Moreover, chromatin structure can also
impact AS through the direct recruitment of splicing factors by
certain chromatin modiﬁcations or through affecting trans-
cription elongation rate16. The detailed mechanisms underlying
the coupling of transcription and splicing regulation still require
much more investigation.
AKAP95 (AKAP8)18 is the only nuclear member of the large
family of A-kinase anchoring proteins (AKAPs), which bind to
protein kinase A and spatiotemprorally regulate cellular
signalling19. In addition, AKAP95 is the founding member
of the AKAP95 family proteins, which also include HA95
(the mammalian AKAP95 paralog) and ZNF326 and all share the
common AKAP95 subtype of the zinc-ﬁnger domains (ZFs)20.
Several different functions have been proposed for AKAP95
(refs 21–23), including mediation of chromatin condensation24,25
and recruitment of HDACs to mitotic chromosomes23. Our
previous work26 has demonstrated that AKAP95 is associated
with the DPY30 subunit of the SET1/MLL complexes, the major
histone H3K4 methyltransferases in mammals, and enhances the
methylation activity of the complexes on chromatin substrate
in vitro. AKAP95 strongly stimulates the expression of a
chromatin reporter gene, and this effect requires both the
N-terminal region (1–100 residues) and the ZFs. We have also
shown that AKAP95 regulates retinoic acid-mediated gene
induction in mouse embryonic stem (ES) cells. The exact role
of AKAP95 in regulating gene expression, however, remains
elusive. To further understand the molecular function of AKAP95
in gene regulation, we took an unbiased proteomic approach to
identify proteins associated with AKAP95. Unexpectedly, we
discovered that AKAP95 mainly associates with many proteins
involved in RNA processing, including hnRNP proteins. This led
our further studies to reveal a functional role of AKAP95 in
regulating pre-mRNA splicing, especially in promoting exon
inclusion in AS, by scaffolding RNAs and RNA processing
factors. Our work reveals a new activity of AKAP95, which may
represent a novel class of splicing factors that bridge the
regulation between transcription and splicing.
Results
AKAP95 binds to RNA processing factors at its N-terminus.
Because the N-terminal region (1–100 residues) of AKAP95 is
highly enriched with Tyr-Gly (YG) motifs (Fig. 1a and
Supplementary Fig. 1a) and required for stimulation of chromatin
reporter expression26, we reasoned that this region may be
associated with factors crucial for gene expression, in addition to
DPY30 complexes. We thus sought to identify its binding
proteins by immunoafﬁnity puriﬁcation of nuclear extracts
derived from HEK293 cell lines that stably express FLAG-HA-
tagged (FH-) full-length human AKAP95 (FH-AKAP95) or FH-
AKAP95 (101–692), followed by mass spectrometric analysis
(Fig. 1b and Supplementary Table 1). We found that the major
AKAP95-assoicated proteins (mass spectrometric protein score
4200) are known to play important roles in many aspects of
RNA processing, including hnRNP M, K, H, F, D and U proteins,
and DDX5, DDX17, DBC1 and RBM14. Proteins with inter-
mediate scores (between 40 and 200) included EWS, PELP1,
NHN1, RNA helicase A, and the other two members of the
AKAP95 family, HA95, and ZNF326. Two SR proteins, SFRS2
and SFRS14, were also detected with relatively low scores. We
note that the abundant hnRNP A1 was not recovered in the
FH-AKAP95 pull-down, suggesting that AKAP95 selectively
interacts with hnRNP proteins. In contrast to FH-AKAP95,
although FH-AKAP95 (101–692) was expressed at a slightly
higher level, its pull-down consisted mainly of AKAP95
(101–692) and its degraded forms (Fig. 1b). None of the other
AKAP95-associated proteins, except for hnRNPs M, H and
F with much lower scores, was recovered in the pull-down of
AKAP95 (101–692; Fig. 1c and Supplementary Table 1),
indicating an important role of the N-terminal region (1–100
residues) for binding the RNA processing factors.
The endogenous association of some of these proteins was
conﬁrmed by their co-immunoprecipitation with AKAP95 from
HeLa cell nuclear extract (Fig. 1d). Although the mass spectro-
metric analysis did not ﬁnd RNA polymerase II (Pol II), our
immunoblotting assays showed that AKAP95 was associated with
Pol II that was unphosphorylated or phosphorylated at serine 5 or
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Figure 1 | AKAP95 is associated with many proteins involved in transcription and RNA processing at its N-terminus. (a) Schematics of domains on
AKAP95. See Supplementary Fig. 1a for sequence and annotations. (b) Coomassie blue-staining of proteins resolved on SDS–polyacrylamide gel
electrophoresis gel following immunoafﬁnity puriﬁcation from the parental (control) and 293 cell lines stably expressing FLAG-HA-tagged (FH-) AKAP95
or AKAP95 (101–692). Major proteins identiﬁed speciﬁcally from the indicated cell line by mass spectrometry are indicated. Lines on the left of the lane
indicate positions of gel excision for mass spectrometry. Proteins in bold have protein scores over 200. (c) The mass spectrometry protein scores of the
identiﬁed hnRNP proteins co-immunoprecipitated with FH-AKAP95 or FH-AKAP95 (101–692) are plotted. (d) Immunoblot analysis of endogenous
AKAP95-associated proteins following immunoprecipitation of HeLa cell nuclear extract by control (normal rabbit IgG) or anti-AKAP95 antibody.
(e) Immunoblot analysis of immunoprecipitation by amylose beads (MBPk) of lysates from 293 cells expressing MBP or MBP fused to AKAP95 wild type
or mutants as indicated. Antibodies for hnRNPs were used for blotting, and membrane was also stained by ponceau S to show the general loading as well as
the comparable precipitation of the MBP or MBP fusion proteins. (f) Immunoblot analysis of immunoprecipitation by anti-FLAG antibody-conjugated resin
(FLAGk) of lysates from 293 cells expressing FH-tagged AKAP95 wild type or mutants as indicated. Antibodies for hnRNP proteins or FLAG epitope were
used for blotting. (g) Direct interaction of AKAP95 with hnRNP F, as shown by immunoblot analysis of the in vitro binding assay for puriﬁed F-AKAP95 or
F-AKAP95 (101–692) with puriﬁed His-hnRNP F that remained bound to Ni resin. Inputs (In.) for F-AKAP95 and F-AKAP95 (101–692) were also shown.
(h) Direct interaction of AKAP95 with hnRNPs M and H1, as shown by immunoblot analysis of the in vitro binding assay for puriﬁed F-AKAP95 or
F-AKAP95 (101–692) with puriﬁed GST (lanes 3 and 4), GST-hnRNP M (lanes 5 and 6) and GST-hnRNP H1 (lanes 7 and 8) that remained bound to
Glutathione resin. Inputs (lanes 1 and 2) for F-AKAP95 and F-AKAP95 (101–692) were also shown.
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2 of its C-terminal domain, although the association of serine 2-
phosphorylated Pol II is less certain due to the overall low signal
(Fig. 1d). The association of AKAP95 with these proteins was
not mediated by RNAs, as effective treatment of the nuclear
extract with RNAse A had little effect on the efﬁciency of the
co-immunoprecipitation (Supplementary Fig. 1b,c).
Consistent with the mass spectrometric analysis, our immuno-
blotting analysis from separate pull-down assays also demon-
strated that AKAP95 (101–692) did not bind efﬁciently to
hnRNPs M, F or H1 (Fig. 1e). However, AKAP95 ZFC-S mutant
(with Cys to Ser mutation in both zinc ﬁngers, Supplementary
Fig. 1a)26 bound as efﬁciently to these hnRNPs as the wild-type
AKAP95 (Fig. 1e). Importantly, the N-terminal region of
AKAP95 was sufﬁcient to mediate binding to these hnRNPs, as
shown by the efﬁcient co-immunoprecipitation of these proteins
by FH-AKAP95 (1–210) and FH-AKAP95 (1–340; Fig. 1f).
AKAP95 (1–100) could not be tested due to its poor expression or
stability in cells. Moreover, we demonstrated a direct binding of
puriﬁed hnRNPs F, H1 and M with AKAP95, but not with
AKAP95 (101–692; Fig. 1g,h). Furthermore, AKAP95 appeared to
bind more strongly with hnRNP M than H1 in vitro (Fig. 1g,h),
suggesting a differential binding afﬁnity between AKAP95 and
hnRNPs. These results indicate that the N-terminal region of
AKAP95 critically mediates binding to the RNA processing
factors including selective groups of hnRNPs, while its ZFs are
dispensable for binding to these factors.
AKAP95 directly regulates splicing of a minigene pre-mRNA.
The physical association of many RNA processing factors with
AKAP95 suggests a potential function of AKAP95 in RNA
processing such as regulation of pre-RNA splicing. We thus set
out to test this hypothesis, starting with a minigene splicing
system (Fig. 2a) that allows a convenient splicing readout by a
double reporter assay27. We found that the splicing efﬁciency of
the minigene in human 293 cells was enhanced by overexpression
of AKAP95, as well as any of the other two members of the
AKAP95 family, HA95, and ZNF326 (Fig. 2b). Conversely, the
minigene was spliced less efﬁciently following a short-hairpin
RNA (shRNA)-mediated knockdown (KD) of Akap95 in mouse
NIH3T3 cells, as demonstrated by both the double reporter and
the PCR-based assays (Fig. 2c). Similarly, the splicing efﬁciency of
the minigene was reduced by AKAP95 KD via small-interfering
RNAs (siRNAs) either speciﬁc for the 30-untranslated region
(30UTR) of AKAP95 or with mixed speciﬁcity for AKAP95
(Smart-pool siRNA, SMP) in human 293 cells (Fig. 2d).
Importantly, splicing was rescued by wild-type AKAP95 that
was expressed near the endogenous level, but not the AKAP95
(101–692) or AKAP95 ZFC-S mutants that were expressed at
similar levels as wild type (Fig. 2d). These results show that the
efﬁcient minigene splicing in cells requires AKAP95, and both
its N-terminal 100 residues and ZFs are important for this
regulation.
We next asked if AKAP95 was directly involved in splice
regulation in a cell-free splicing reaction. First we showed that our
HeLa cell nuclear extract could efﬁciently splice the minigene
pre-mRNA in a manner that was sensitive to salt concentration
and heat (Supplementary Fig. 2a), consistent with the established
in vitro splicing system28. The derived PCR products were also
sequence-veriﬁed to represent unspliced and spliced species. We
showed that antibody-mediated AKAP95 depletion markedly
reduced the splicing of the minigene transcript (Fig. 2e, left gel).
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Figure 2 | AKAP95 is directly required for efﬁcient minigene splicing.
(a) Diagram of the minigene splice reporter. ‘xxx’ represents three stop
codons inserted into the intron. Arrows represent PCR primers used in c.
(b) 293 cells co-transfected with the splice reporter and the indicated
plasmids were subject to the double reporter assay. hnRNP G and Tra2b,
known to be negative and positive regulators of the minigene splicing,
respectively27, were included as controls. Average±s.d. from four
independent transfections are plotted. *Po0.01, **Po0.001 between
vector transfection and the indicated sample. (c) The splice reporter was
transfected into the NIH3T3 cells after stable infection of control or Akap95
shRNA. Splicing was determined in two ways including the double reporter
assay (top) and the PCR-based assay (bottom). Average±s.d. from three
biological repeats are plotted. **Po0.001 between the two samples.
(d) 293 cells co-transfected with indicated siRNAs and plasmids were
subject to immunoblotting with indicated antibodies (top) and the double
reporter assay (bottom). NT is a non-targeting siRNA. GL2 siRNA targets
the luciferase RNA. Average±s.d. from three independent transfections are
plotted. *Po0.01 between the indicated sample and either sample 1 or 4.
P40.05 between samples 1 and 4. (e) In vitro splicing assays using two
different batches of HeLa nuclear extracts, with batch 1 (left gel) much
more concentrated and thus more active than batch 2 (right gel). Batch 2
nuclear extract was from HeLa cells with AKAP95 stably knocked down by
shRNA. HeLa nuclear extract was depleted of AKAP95 by antibody when
indicated by ‘þ ’. Two different doses of puriﬁed recombinant AKAP95 or
its mutants were added as indicated. Immunoblotting (top) indicates the
levels of the exogenous wild type or mutated AKAP95. The Percentage of
spliced product in the total product (percent spliced) was calculated based
on quantiﬁcation of band intensities, and plotted as average±s.d. from
three independent splicing assays (bottom). *Po0.01, **Po0.001 between
the indicated sample and any of samples 2, 5–8.
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To achieve a cleaner AKAP95 depletion, we used HeLa cells in
which AKAP95 had been stably knocked down by shRNA, and
also used a modiﬁed protocol to derive nuclear extract from these
cells at a much less protein concentration. Further AKAP95
depletion by antibody from this nuclear extract reduced the
pre-mRNA splicing (Fig. 2e, compare lanes 1 and 2 on the right
gel). Importantly, addition of two different doses of puriﬁed wild-
type AKAP95, but not the AKAP95 (101–692) or AKAP95 ZFC-S
mutants (Supplementary Fig. 2b) at similar levels, nearly fully
restored splicing in this cell-free system (Fig. 2e). These results
indicate that AKAP95 directly regulates the minigene pre-mRNA
splicing, and both its N-terminal region and ZFs are required for
the direct regulation.
AKAP95 directly regulates alternative splicing of FAM126A.
We next sought an endogenous target of AKAP95 for splicing
regulation. Considering the direct interaction of AKAP95 and
hnRNP F, we examined the effect of AKAP95 KD on splicing
events that were established to be regulated by hnRNP F,
including the AS of exon 11 of the FAM126A transcript
(FAM126A-006 ENST00000409923)12. Comparable to the effect
of hnRNP F KD (Fig. 3a), AKAP95 KD mediated by speciﬁc
shRNA or siRNA in different human cell lines consistently
resulted in increased skipping (reduced inclusion) of exon 11 in
FAM126A transcript (Fig. 3a). Importantly, AKAP95 KD did not
affect the expression of hnRNPs at the RNA or protein levels
(Supplementary Fig. 3a,b). Moreover, Akap95 KD mediated by
two different shRNAs in mouse ES cells also impaired inclusion
of exon 10 (the corresponding exon of the human exon 11) in
mouse Fam126a (Fig. 3a, right, and Supplementary Fig. 3a,b),
suggesting a conserved role of AKAP95 in regulating the AS of
FAM126A.
To determine if AKAP95 directly regulates FAM126A splicing,
we performed RNA immunoprecipitation (RIP) assays following
either formaldehyde- or ultraviolet-mediated crosslinking of cells.
Formaldehyde tends to provide higher crosslinking efﬁciency
than ultraviolet, but it also crosslinks proteins with interacting
proteins, while ultraviolet-crosslinking is only effective for direct
RNA-protein contact. To achieve robust RIP signals in our earlier
RIP assays, we induced the expression of FH-AKAP95, FH-
AKAP95 (101–692) or FH-AKAP95 ZFC-S to high levels in 293
cells (Supplementary Fig. 3c), and performed formaldehyde
crosslinking. Our RIP assays included extensive DNAse treatment
followed by reverse transcription of puriﬁed RNAs into DNAs,
which were used in quantitative PCR (qPCR) reactions.
Moreover, the qPCR signals were abolished when the reverse
transcriptase SS III was omitted from the reaction (Supple-
mentary Fig. 3c), indicating that the RIP signals were indeed from
RNAs.
Our RIP-qPCR assays demonstrated that FH-AKAP95 bound
to three major sites in the region around the AKAP95-regulated
exon 11 of FAM126A (Supplementary Fig. 3c). The ﬁrst two sites
are at the intronic regions near the junctions to exons 10 and 11;
and the last one is at exon 12, which contains the 30UTRs. These
RIP signals were speciﬁc to FH-AKAP95, as they were largely
absent from the negative control cells (Supplementary Fig. 3c).
RNA binding of FH-AKAP95 (101–692) was largely similar
(or modestly reduced in certain regions) to that of FH-AKAP95,
but FH-AKAP95 ZFC-S was defective in binding of RNA at all
three major sites, despite their similar expression levels
(Supplementary Fig. 3c). These results indicate that the ZFs, but
not the N-terminal 1–100 residues, are critical for AKAP95
binding to FAM126A pre-mRNA.
We then performed RIP assays following ultraviolet cross-
linking to detect direct RNA-protein binding under conditions
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Figure 3 | AKAP95 directly regulates AS of FAM126A. (a) PCR assays for
skipping of FAM126A exon 11 following AKAP95 KD in human 293 and
H1299 cells and also in mouse ES cells using indicated shRNAs (for 293 and
ES cells) or siRNAs (for H1299). Scramble shRNA was used as control
shRNA, and GL2 siRNA targeting luciferase RNA was used as control
siRNA. Following quantiﬁcation of band intensities by the ImageJ
programme, the percentage of the PCR product representing exon
11-skipped transcript in the total transcripts was calculated and shown as
‘percent skipped’ on the y axis. For all cells, average±s.d. from three
biological repeats are plotted. *Po0.01, **Po0.001 between the indicated
sample and their corresponding control sample. (b) Expression of FH-
AKAP95 or the indicated mutants was induced by doxycycline in stable Flp-
In T-REx 293 cell lines. The control is the parental Flp-In T-REx 293 cells.
The expression levels were shown by western blotting for AKAP95 (left).
Anti-FLAG RIP assays were performed in these cell lines after ultraviolet-
crosslinking, and followed by qPCR assays with a series of primers
(represented by dots on the curves) at the FAM126A locus (diagram at the
very bottom of this ﬁgure). Another biological repeat of RIP assay is shown
in Supplementary Fig. 3d. (c) RIP assays using control (normal rabbit IgG)
or anti-AKAP95 antibody were performed in 293 cells after ultraviolet-
crosslinking, and followed by qPCR by the same series of primers as in b at
the FAM126A locus. Two more independent biological repeats are shown in
Supplementary Fig. 3e. (d) 293T cells were transfected with empty vector
(control) or the FH-hnRNP F plasmid to express sub-endogenous level of
FH-hnRNP F using a plasmid dose equivalent to that circled in
Supplementary Fig. 3g. Anti-FLAG RIP assays were performed after
ultraviolet-crosslinking, and followed by qPCR at FAM126A. Two more
independent biological repeats are shown in Supplementary Fig. 3f.
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that allowed comparable expression of FH-AKAP95 and the
mutants to the endogenous level (Fig. 3b and Supplementary
Fig. 3d). Although the overall signal intensity was lower, the RIP
results under these conditions (Fig. 3b and Supplementary
Fig. 3d) are highly similar to our previous results on formal-
dehyde-crosslinked RIP assays for overexpressed FH-AKAP95
(Supplementary Fig. 3c). Moreover, we also performed RIP
assays for endogenous AKAP95 following ultraviolet-crosslinking
(Fig. 3c and Supplementary Fig. 3e), and the proﬁle highly
resembles that following formaldehyde-crosslinking, further
supporting that AKAP95 directly binds to FAM126A pre-mRNA.
We also showed that Akap95 in mouse ES cells bound to largely
similar regions near the Akap95-regulated exon 10 of Fam126a
(Supplementary Fig. 3h), indicating a conserved AKAP95 binding
pattern for regulating exon inclusion in FAM126A.
We also determined the direct binding of hnRNP F to the
FAM126A pre-mRNA following ultraviolet-crosslink of 293 cells
expressing sub-endogenous level of FH-hnRNP F (Supplementary
Fig. 3g), as our anti-hnRNP F antibody did not work robustly in
RIP for the endogenous hnRNP F. Consistent with the direct
binding between hnRNP F and AKAP95 (Fig. 1g), FH-hnRNP F
was also found to directly bind to the same intronic sites as
AKAP95 (Fig. 3d and Supplementary Fig. 3f). These results thus
establish a direct and joint regulation of FAM126A exon 11
inclusion by the interacting AKAP95 and hnRNP F proteins.
AKAP95 binds to intronic regions of cellular pre-mRNAs. We
then determined binding of the endogenous AKAP95 to the
human transcriptome by deep sequencing analyses of the RNAs
enriched from the anti-AKAP95 RIP assays in 293 cells following
formaldehyde crosslinking due to its robustness. Extensive
binding sites of the endogenous AKAP95 were identiﬁed by the
RIP-seq analyses, and the speciﬁcity of the AKAP95 RIP signals
was supported by the diminished RIP signals following AKAP95
KD (Fig. 4f and Supplementary Fig. 3b). Analyses of the RIP-seq
results show that AKAP95 binds primarily to intronic regions
(Fig. 4a,f, and Supplementary Fig. 4e,f), especially in close
proximity (within 500 nt) to exon–intron junctions (Fig. 4a,d).
Although AKAP95 also binds to the 50 and 30UTRs as well as
exons (Fig. 4a,b), the binding at these regions is less efﬁcient than
the intronic regions (Fig. 4c), as these regions are much more
abundant than the intronic regions in the total RNA input.
AKAP95 tends to bind to AU-rich motifs, although several
different motifs are associated with AKAP95 (Fig. 4e).
To understand the domain contribution to the transcriptome
binding, we also determined the RNA-binding proﬁles of
the stably expressed wild type and mutated AKAP95. The
RNA-binding proﬁle of the overexpressed wild-type FH-AKAP95
is overall similar to that of the endogenous AKAP95 (Fig. 4f and
Supplementary Fig. 4a–c,e,f), indicating that its overexpression
did not grossly change the transcriptome binding. The RIP-seq
results also conﬁrmed AKAP95 binding to the intronic regions
near the regulated exon 11 of FAM126A (Supplementary Fig. 4e).
In comparison to the wild type, AKAP95 (101–692) mutant
showed similar binding pattern at many transcripts, with either
unaffected or modestly reduced signal levels, but the AKAP95
ZFC-S mutant showed markedly reduced binding to the
transcripts (Fig. 4f and Supplementary Fig. 4e,f). While these
results suggest that the N-terminal region contributes to the RNA
binding of AKAP95, they clearly indicate a critical role of the zinc
ﬁngers of AKAP95 in transcriptome binding.
We also performed RIP assays for both the overexpressed wild
type or mutant AKAP95 and endogenous AKAP95 following
ultraviolet-crosslinking of cells, and determined their binding by
qPCR at several sites that were shown to be bound by AKAP95 at
high levels based on the formaldehyde-crosslinked RIP-seq
results. Our results from the ultraviolet- and formaldehyde-
crosslinking methods are highly similar for most of these sites,
although ultraviolet-crosslinking generated overall lower signal
levels (Supplementary Fig. 4d). These results indicate that our RIP
assays reﬂect mostly direct binding of AKAP95 with pre-mRNAs,
although indirect binding may also contribute to the RIP signals.
AKAP95 mainly promotes inclusion of exons globally. To
assess the global impact of AKAP95 on AS, we depleted AKAP95
in human 293 cells and mouse ES cells, and performed RNA-seq
followed by DEXseq analysis29 to identify the differential exon
usage in the cellular mRNAs. DEXseq analysis offers reliable
control of false discoveries by taking biological variation into
account29. AKAP95 KD resulted in much more events of exon
usage decrease than increase in both 293 (Fig. 5a,b and
Supplementary Data 1) and ES cells (Supplementary Fig. 5a,b
and Supplementary Data 1), suggesting that AKAP95 regulates
AS globally with a preference to promote exon inclusion. We
validated some of the differential exon usage to be bona ﬁde exon
inclusion or skipping events by PCR-based assays (Supple-
mentary Fig. 5d).
The effects on exon usage reduction are not merely a technical
bias due to the reduced expression of some genes, because
(1) DEXseq normalizes each exon signal level against the total exon
signal levels in the gene29, (2) the vast majority of the genes with
signiﬁcantly affected exon usage were not signiﬁcantly affected in
expression by AKAP95 KD in 293 cells (Fig. 5c,d), (3) our PCR
data conﬁrms the effects on the skipping or inclusion of speciﬁc
exons instead of the expression of genes (Supplementary Fig. 5d)
and (4) while the expression of similar numbers of genes was up- or
down-regulated following Akap95 KD in the mouse ES cells
(Supplementary Fig. 5c), the usage of much more exons was
increased than decreased (Supplementary Fig. 5a,b).
To determine if the alternative exon usage was a direct effect of
AKAP95 activity, we compared the AKAP95 physical targets
(based on AKAP95 RIP-seq) with its functional targets (based on
mRNA-seq). Genes with AKAP95 bound at its introns were
signiﬁcantly overlapped with genes that showed signiﬁcant
change (either decrease or increase) in exon usage on AKAP95
KD (Fig. 5e), suggesting that many of the differential exon usage
events were a direct effect of AKAP95 activity at the RNAs.
To identify biological pathways that the AKAP95 targets are
involved in, we performed gene ontology analysis for both the
functional and physical targets of AKAP95. Our results reveal a
signiﬁcant enrichment of chromatin/transcription regulators and
RNA processing factors in the genes that showed differential exon
usages on AKAP95 KD in 293 cells (Fig. 5f) and in mouse ES cells
(Supplementary Fig. 5e), as well as in the genes with AKAP95
bound at introns (Fig. 5f, black bars). These results suggest that
AKAP95 can potentially regulate global gene expression through
direct and indirect control of chromatin, transcription and RNA
processing (Supplementary Fig. 5f).
AKAP95 and selected hnRNPs co-regulate alternative splicing.
To further understand the functional relationship of AKAP95
with different hnRNP proteins, we also examined the effects of
AKAP95 KD on exon inclusions previously shown to be affected
by depletion of various hnRNPs12. We found that, while AKAP95
KD did not affect the expression of hnRNPs (Supplementary
Fig. 3a,b), it affected the exon usage in the same direction as the
depletion of hnRNP F, U and H1, but not A1 (Fig. 6a). This is
consistent with the physical interaction of AKAP95 with hnRNPs
H/F and U, but not A1 (Fig. 1b and Supplementary Table 1).
Importantly, we show that AKAP95 binds to the introns
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immediately ﬂanking the regulated exons (Fig. 6b and Supple-
mentary Fig. 6a), and the binding regions often overlap with
those bound by hnRNPs H/F and U. Interestingly, although
hnRNP A1 and AKAP95 also have overlapping binding regions
in immediately ﬂanking introns of certain genes (Supplementary
Fig. 6a), these proteins often have different effects on the
inclusion of the nearby exons (Fig. 6a). These results further
strengthen our model for a direct control of exon inclusion by
AKAP95 through selective coordination with hnRNPs.
AKAP95 interacts with itself. A loop-out model of action has
been proposed for splice regulation by hnRNP A/B and hnRNP
F/H proteins through interacting with itself or a different hnRNP
protein13,14. We sought to assess if AKAP95 might act in a similar
manner. We found that AKAP95 efﬁciently interacts with itself,
as the FH-AKAP95 could be co-precipitated by the co-transfected
AKAP95 fused to maltose-binding protein (MBP), but not by
MBP alone (Fig. 7a). We also found that AKAP95 directly
interacts with itself, as puriﬁed AKAP95-MBP, but not MBP,
could efﬁciently bind to puriﬁed F-AKAP95 (Fig. 7b). While
AKAP95 (101–692) and AKAP95 ZFC-S were able to bind to
AKAP95, AKAP95 (211–692) had a markedly reduced binding
capacity with AKAP95. Moreover, AKAP95 (1–210) was sufﬁ-
cient in mediating AKAP95 binding (Fig. 7a). Therefore, the
N-terminal region 1–210, especially 101–210, probably plays an
important role in AKAP95 self-interaction. These data provide
the possibility that, by binding to each end of the RNA intronic
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Figure 4 | AKAP95 preferentially binds to introns of cellular pre-mRNAs. (a) Distribution of the numbers of endogenous AKAP95 binding sites within
different categories of genic regions, as calculated from MACS peak counts. The colour legend applies to a–c. Results in a–e are from anti-AKAP95 RIP
assays in 293 cells. (b) Number of AKAP95 binding sites in each 1 million nucleotides of different genic regions. (c) AKAP95 binding efﬁciencies to
different categories of genic regions, as calculated as the ratio of the anti-AKAP95 RIP coverage over the input RNA coverage in the corresponding genic
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the corresponding input RNA proﬁle (Input, bottom) are shown. For the diagram at the bottom, solid line, intron; open box, exon. UTR-containing exons are
excluded from the analysis on the right. (e) The most enriched sequence motifs bound by AKAP95 in the transcriptome. (f) Representative RIP proﬁles. In
blue are the Anti-FLAG RIP-seq proﬁles from parental 293 cells (control) or 293 cells stably expressing the FH-tagged AKAP95 wild type or mutants as
indicated. In red are the anti-AKAP95 RIP-seq proﬁles from parental 293 cells (control) or 293 cells stably expressing AKAP95 microRNAs (miR#12, shown
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sequences and self-interaction, AKAP95 may help bring the two
ends of an intron into proximity and thus facilitate the splice site
communication and intron deﬁnition (Supplementary Fig. 6b).
Discussion
Although pre-mRNA splicing is a major and key step in the
genetic information ﬂow, only a handful of splicing regulators
have been shown to be responsible for controlling the large
number of AS events in cells8. Recent studies20,30 have identiﬁed
hundreds of RNA-binding proteins that may potentially regulate
many aspects of RNA biology including splicing, but the
functional roles of many of them have not been characterized
in RNA metabolism. Among these identiﬁed RNA-binding
proteins are all three members of the AKAP95 family that
share the common ZFs. In addition to a role in transcriptional
co-activation shown in our previous work26, several lines of
functional evidence from this study (summarized as follows)
collectively support a primarily positive role of AKAP95 in pre-
mRNA splice regulation. (1) AKAP95 overexpression enhances
splicing of a minigene reporter, and its depletion reduces splicing
of the minigene. (2) AKAP95 is required for efﬁcient splicing of a
pre-transcribed RNA in vitro. (3) Depletion of AKAP95 in both
human 293 cells and mouse ES cells primarily result in reduced
exon inclusion events. The functional evidence is well in line with
our biochemical results that AKAP95 binds to many RNA
processing factors including selective groups of hnRNPs, and also
directly to pre-mRNAs with a strong preference for introns.
The predominant location of AKAP95 in the proximal
intronic regions, which are enriched with many intronic
splicing regulatory elements31–33, is consistent with its role in
regulating splice site selection.
We speculate that AKAP95 might facilitate the splice site
communication through both RNA-binding and protein–protein
interaction (Supplementary Fig. 6b), similar to the proposed
mechanisms for hnRNP A1 and H/F13,14. Such interactions may
involve AKAP95 with selective hnRNPs and/or with itself. This
model is supported by the functional and biochemical data on at
least a few examined target transcripts (for example, FAM126A
and WDR85) of AKAP95 and hnRNP H/F, where AKAP95 binds
to both ends of an intron next to the regulated exon. The
generality of this model towards other AKAP95 targets awaits
further studies, including high-resolution mapping of AKAP95-
binding sequences and more detailed biochemical dissections.
Our results suggest that the other two members of the AKAP95
family, HA95 and ZNF326, can physically associate with AKAP95
(Fig. 1b and Supplementary Table 1) and also regulate RNA
splicing (Fig. 2b), yet AKAP95 clearly has non-redundant roles as
reﬂected by effects on splicing following its depletion. It will be
interesting to understand if these AKAP95 family members
regulate RNA processing by similar or different mechanisms, and
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Figure 5 | AKAP95 functions to primarily promote exon inclusion.
(a) Volcano plot for exons whose normalized usage was signiﬁcantly
affected (false discovery rate or Padjo0.01 for red and yellow, red for fold
change over 2) or not (Padj40.01, blue) in 293 cells. Fold change is the
ratio of the normalized exon level in AKAP95 KD over that in control cells.
See Supplementary Data 1 for the gene list. (b) Pie chart showing the
number of exons whose normalized usage was signiﬁcantly (Padjo0.01)
reduced (blue) or enhanced (red) over twofold on AKAP95 KD in 293 cells.
(c) Volcano plot for genes whose expression was signiﬁcantly affected
(Padjo0.01 for red and yellow, red for fold change over 2) or not
(Padj40.01, blue) in 293 cells. Fold change is the ratio of the normalized
exon level in the AKAP95 KD over that in the control cells. (d) Venn
diagram showing an insigniﬁcant overlap between genes that contain exons
signiﬁcantly affected (reduced and enhanced) over twofold and genes
whose expression was signiﬁcantly changed on AKAP95 KD in 293 cells.
The two-tailed P value was calculated by w2 test with Yates’ correction.
(e) Venn diagram showing signiﬁcant overlap between genes that contain
exons signiﬁcantly (Padjo0.01) reduced (left) or enhanced (right) over
twofold on AKAP95 KD and genes whose transcripts were bound by
AKAP95 at the intronic regions in 293 cells. The two-tailed P value was
calculated by w2 test with Yates’ correction. (f) Gene ontology analysis of
functional and physical target genes of AKAP95. Blue and red bars
represent genes containing signiﬁcantly (Padjo0.01) affected exons over
twofold on AKAP95 KD in 293 cells, based on 2,189 DAVID IDs with down-
regulated exons and 657 DAVID IDs with up-regulated exons. Black bars
represent genes whose transcripts were bound by AKAP95 at the intronic
regions, based on 1381 DAVID IDs corresponding to 2,000 intron-bound
MACS peaks (with the highest peak scores) from the anti-AKAP95 RIP
assays in 293 cells. Gene functions in light blue shade are for chromatin and
transcription regulation, and gene functions in pink shade are for RNA
binding and processing.
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how cells regulate their differential usage and/or function in RNA
processing. ZNF326 has been shown to regulate AS through
promoting transcriptional elongation rate34, and thus reducing
the time window for the weaker splice site recognition before
being out-competed by the emerging stronger splice sites. Two
lines of evidence suggest that AKAP95 probably does not regulate
splicing through the identical mechanisms proposed for ZNF326.
(1) Our in vitro splicing results indicate that AKAP95 is capable
of stimulating splicing even when it is uncoupled from
transcription. (2) Exon skipping is much preferred over
inclusion upon AKAP95 KD, which is opposite to the preferred
exon inclusion upon ZNF326 KD (ref. 34). However, our
results do not exclude the possibility that AKAP95 may
regulate co-transcription splicing in cells, potentially through a
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kinetic effect of transcription elongation on exon inclusion with
differential consequences.
Our previous26 and this studies have established a physical and
functional connection of AKAP95 with both transcription and
pre-RNA splicing. The N-terminal (1–100) and ZFs of AKAP95
are required for its activity in transcription co-activation as well
as splice regulation. Importantly, truncation of the N-terminal
region (1–100) is unlikely to affect the overall structure inte-
grity of AKAP95, because mutants lacking this or more
extensive N-terminal region retain full activities in (i) mediating
chromatin condensation35, (ii) binding to a reporter promoter on
chromatin26 and (iii) binding to many regions in the trans-
criptome. Rather, the N-terminal region is necessary and
sufﬁcient in mediating binding to many hnRNP proteins
(Fig. 1f). In addition to RNA Pol II, many other AKAP95
N-terminus-associated proteins including PELP1 (refs 36,37),
RNA helicase A (refs 38–40), EWS (ref. 41), DDX5 and DDX17
(ref. 42) and RBM14 (CoAA; ref. 43) have all been previously
shown to be involved in transcription activation. Therefore, the
role of the N-terminal region in both transcription co-activation
and splice regulation is most likely mediated by its binding to
important factors in both processes. In addition to protein
interactions, the N-terminal YG-rich region may also contribute
to the RNA-binding capacity of AKAP95, as its deletion modestly
impairs binding at some pre-mRNA regions. This is consistent
with the observation that YG/RG motifs are frequently found in
combination with RNA-binding domains in many RNA-binding
proteins20. On the other hand, the ZFs are critical for AKAP95 to
regulate RNA processing by binding to pre-mRNAs, but their role
in transcription co-activation remains elusive. It is worth noting
that the zinc-ﬁnger subtype in AKAP95 is a new RNA-binding
domain that was suggested20 but has not been previously
experimentally demonstrated. The zinc ﬁngers of AKAP95 are
important in mediating chromosome condensation35, and might
directly or indirectly facilitate AKAP95 association with
chromatin. As the communication between transcription and
splicing goes both way16, it also remains possible that AKAP95
may regulate transcription via its direct impact on RNA binding
and splicing.
Cross-regulation of RNA-binding proteins and signal ampli-
ﬁcation in splicing cascades have emerged as general features of
splicing networks, and may serve to stabilize splicing patterns
within a cellular state or to expand and reinforce the splicing
network44. AKAP95 directly modulates the processing of many
RNAs whose protein products are involved in RNA processing
and chromatin or transcriptional regulation (Fig. 5f and
Supplementary Fig. 5e). Consistent with the direct hnRNPs-
AKAP95 interaction, many hnRNP proteins are also known to
affect the splicing of RNAs encoding RNA-processing factors12.
Therefore, AKAP95 may coordinate with different hnRNPs to
create regulatory cascades for gene expression and function
(Supplementary Fig. 5f).
In addition to transcription and splice regulation, AKAP95
may also regulate other steps in RNA processing, as it binds to
pre-mRNA UTRs and many factors that play multiple roles in
RNA processing. Indeed, AKAP95 binds to 30 UTR of LDHA
mRNA together with the regulatory subunits of the protein kinase
A, and regulates the stability of that mRNA22. NHN1 (ZC3H18)
and ZCCHC8, which we found in the AKAP95 immuno-
precipitate, are also associated with the cap-binding complex45,
nuclear exosome targeting complex46 and pre-catalytic spliceo-
somal complexes47, and are implicated in multiple steps in RNA
processing and metabolism.
Mutations in FAM126A have been causally linked to
hypomyelination and congenital cataract due to the dysregulation
of its pre-mRNA splicing and the consequent deﬁciency of its
protein product, hyccin48,49. Inclusion of FAM126A exon 11,
which is regulated by AKAP95 and hnRNP F, leads to a
C-terminally truncated hyccin protein (419 compared with 521
residues). It is unclear whether and how such truncation affects
the protein function and the potential connection to the disease,
but it shows how AKAP95 might regulate human pathology via
splice regulation. AKAP95 has also been implicated in
modulation of head growth and autism50, and found to be
signiﬁcantly overexpressed in rectal cancer together with certain
cyclin genes51. The latter is consistent with the strong enrichment
of the GO term ‘cell cycle’ in the AKAP95 bound or regulated
targets (Fig. 5f and Supplementary Fig. 5e), and also with the
ﬁnding that hnRNPs (many of which physically and functionally
associate with AKAP95) directly target a large number of cancer-
associated genes12.
Methods
Characterization of protein interactions with AKAP95. The FH-AKAP95 and
FH-AKAP95 (101–692) cell lines were made by co-transfecting Flp-In-293 cells
(f293 cells, Invitrogen) with pOG44 plasmid and either an FH-AKAP95-pcDNA5
or an FH-AKAP95 (101–692)-pcDNA5 plasmid, followed by Hygromycin B
selection for stable clones. Nuclear extracts were obtained from these cell lines by a
modiﬁed Dignam procedure52, incubated with anti-FLAG M2 agarose beads
(Sigma) in BC300 (50mM Tris (pH 7.4), 300mM KCl, 20% glycerol, 0.2mM
EDTA) with 0.1% NP40 at 4 C for 6 h and extensively washed with BC300, 0.1%
NP40 followed by BC100, 0.1% NP40. The bound proteins were eluted with
0.4mgml 1 FLAG peptide (Sigma) in BC100 with 0.1% NP40, resolved on
SDS–polyacrylamide gel electrophoresis and visualized by coomassie staining.
The entire gel lanes were sliced into indicated bands and proteins were subjected
to matrix-assisted laser desorption/ionization mass spectrometry. Common
background proteins (for example, keratins and tubulins) and the proteins found in
the pull-down from the extract of control cells were excluded from the list
of interacting proteins. Co-immunoprecipitation of endogenous protein
association was carried out in HeLa cell nuclear extract in BC300, 0.1% NP40.
Co-immunoprecipitation of overexpressed AKAP95 (and its mutants) with
endogenous proteins was performed by transfecting the indicated constructs into
293T cells followed by IP with anti-FLAG M2 agarose beads in cell lysates in
BC300, 0.1% NP40. For directly interaction of AKAP95 and hnRNP F, F-AKAP95
and F-AKAP95 (101–692) were recombinantly expressed in sf9 cells and puriﬁed
as described in our previous publication26. Brieﬂy, Flag-tagged AKAP95, AKAP95
(101–692) or AKAP95 ZFC-S cDNA was inserted into the pFastBac1 vector
(Invitrogen) and baculoviruses were generated according to the Bac-to-Bac
Baculovirus Expression System (Invitrogen) protocols. Baculovirus-infected sf9
cells were lysed in BC500 with 0.05% NP40, 1mM DTT and protease inhibitor
cocktail (Roche). The lysate was incubated with anti-FLAG M2 agarose beads
(Sigma), and the beads were extensively washed with the lysis buffer followed by
further wash in BC100 with 0.05% NP40. Bound proteins were eluted with
0.4mgml 1 FLAG peptide (Sigma) in BC100 with 0.05% NP40. His-tagged
hnRNP F was puriﬁed from sf9 cells infected with baculovirus expressing
His-hnRNP F (generously provided by Benoit Chabot, University of Sherbrooke,
Canada) using Ni-NTA resin (GE healthcare). hnRNPs M and H1 cDNAs
were ampliﬁed from 293 cell cDNAs and cloned into pGEX-4T-1 vector
(GE Healthcare). glutathione S-transferase (GST), GST-hnRNP M and GST-hnRNP
H1 were induced to express in BL21 (DE3) E.coli by 0.5mM of isopropyl b-D-
thiogalactopyranoside for 5 h at 22 C, and puriﬁed using glutathione sepharose 4B
resin (GE Healthcare) without elution. The resin-bound hnRNP proteins were used
in the binding assay with puriﬁed F-AKAP95 and F-AKAP95 (101–692) proteins in
BC200, 0.1%NP40. For direct self-interaction of AKAP95, MBP and AKAP95-MBP
fusion proteins were puriﬁed from sf9 cells infected with corresponding baculo-
viruses using amylose resin (New England BioLabs, E8021S) and remained bound to
the resin after extensive washing. The resin-bound proteins were used in the binding
assay with puriﬁed F-AKAP95 protein in BC200, 0.05% NP40.
Antibodies. Antibodies were obtained commercially. From Santa Cruz
Biotechnology: anti-AKAP95 (sc-10766, 1:500); anti-DDX5 (sc-32858, 1:500);
anti-hnRNP M (sc-20002, 1:500); hnRNP F (sc-10045, 1:500); anti-His (sc-803,
1:500); and anti-RNA Pol II (sc-899, 1:500). From others: Anti-hnRNP A1
(Novus Biologicals, NB100–672, 1:2,000), anti-Pol II (Covance, MPY-127R for
clones 8WG16, H14 and H5, 1:500), anti-hnRNP H (Bethyl Laboratories,
A300–511A, 1:2,000); DDX17 (Bethyl Laboratories, A300–509A, 1:2,000); anti-HA
(Abcam, ab9110, 1:1,000); anti-GAPDH (Chemicon, MAB374, 1:5,000); anti-FLAG
(Sigma, A8592, 1:1,000); anti-FLAG (Sigma, A2220, M2 beads); and anti-MBP
(New England BioLabs, E8032S, 1:5,000).
Splice reporter assay. The double reporter splicing assay was performed on
pTN24 reporter plasmid27. Brieﬂy, cells were transfected with relevant plasmids or
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siRNA using Lipofectamine 2000 reagent (Life Technologies), and harvested 48 h
after transfection. b-galactosidase and luciferase activities were measured using
Dual-Light System (Applied Biosystems).
In vitro splicing assay. In vitro splicing assay was performed using published
protocols28. Brieﬂy, we used primers (50-CGCGGATCCGTACTCCCTCTCA
AAAGC-30 and 50-CCGGAATTCCTTCTCCGCCTGAGCCTC-30) in a PCR
reaction to amplify the DNA fragment containing the exon–intron–exon structure
from the pTN23 plasmid27 (which does not have a T7 promoter), and cloned it
into the pBluescript II KS ( ) plasmid (which has a T7 promoter) between
BamHI and EcoRI sites. This construct was then linearized by EcoRI and used as
substrate in the in vitro transcription reaction mediated by T7 RNA polymerase
(Promega Part# 9PIP207). A standard splicing reaction contained spliced RNA
(0.01–0.1 nM), 20% HeLa nuclear extract, 50 and 100 ng recombinant proteins
when indicated, 1mM ATP, 20mM creatine phosphate, 3.2mM MgCl2, 10U
ribonuclease inhibitor, 1mM DTT, 60mM KCl and 12mM HEPES-KOH (pH 7.9).
The reaction volume was 25ml. Following incubation at 30 C for 2 h, reactions
were proteinase K digested in 200ml with 10mM Tris (pH 7.5), 1% SDS, 0.15mM
NaCl, 1mM EDTA and 0.2 g l 1 proteinase K for 1 h at 42 C, then phenol
chloroform extracted and ethanol precipitated before RT-PCR. To deplete AKAP95
from nuclear extract, AKAP95 antibody was ﬁrst coupled to CNBr-activated
sepharose 4B (Sigma, C9142) following the protocol provided in the Product
Information, and incubated with the nuclear extract at 4 C for 4 h. The
supernatant was used as the depleted extract.
AKAP95 knockdown. We used three different strategies to KD AKAP95 including
siRNAs, shRNAs and microRNAs. Their sequences are shown in Supplementary
Table 2. Indicated cells were transiently transfected with siRNAs and analysed 2–3
days after transfection. Indicated cells were sometimes infected with shRNA-
expressing lentiviruses and selected by puromycin. As an alternative method to
establish stable AKAP95-KD cell lines, we also used the BLOCK-iT Pol II miR
RNAi Expression Vector Kits (Invitrogen) to generate a plasmid expressing two
different AKAP95 microRNA (miR 1 and miR 2) sequences chained as miR1-2-1-2
ﬂanked by BamHI and XhoI restriction sites. The entire microRNAs were trans-
ferred into pcDNA5/FRT/TO (Invitrogen) between BamHI and XhoI, and were
co-transfected with pOG44 (Invitrogen) into Flp-In T-REx 293 cells (Invitrogen).
Stable clones were selected by Hygromycin B, and clones with efﬁcient KD (clones
#8 and #12) on doxycycline induction (100 ngml 1) were selected for further
studies.
PCR and qPCR. To determine gene expression or splicing efﬁciency, total RNAs
were extracted using the RNeasy kit (Qiagen) and reverse-transcribed using the
SuperScript III First-Strand Synthesis System (Invitrogen) with an oligo dT20
primer. For gene expression, qPCR was performed with SYBR Advantage qPCR
Premix (Clontech) on a ViiA7 real-time PCR System (Applied Biosystems). Pri-
mers used are listed in Supplementary Table 3. For splicing detection, PCR was
performed using EmeraldAmp Master Mix (Takara) with 95 C 2min, then 32
cycles of 95 C 20 s, 58 C 30 s and 68 C 50 s. PCR products were resolved on
agarose gel, and the signal intensities of the bands were quantiﬁed by the ImageJ
programme.
RNA immunoprecipitation. Cells were crosslinked with 1.2% formaldehyde
for 15min or irradiated with ultraviolet light at 254 nm, 400mJ cm 2. Cells
(B50 millions) were harvested and lysed in 2ml radio-immunoprecipitation assay
buffer (50mM Tris-HCl pH 7.4, 1% NP40, 0.5% sodium dexoycholate, 0.1% SDS,
1mM EDTA, 150mM NaCl, 1mM DTT, 50 unitsml 1 RNase Out). The cell
lysates were sonicated at Bioruptor (Diagenode) at ‘high mode’ for 60 cycles to
shear to 400–800 bp. After centrifugation, the clear lysate were immunoprecipitated
at 4 C overnight. Beads were washed by low salt (0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris-HCl pH 8.1, 150mM NaCl), high salt (0.1% SDS, 1%
Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.1, 500mM NaCl), LiCl immune
(0.25M LiCl, 1% NP40, 1% deoxycholic acid, 1mM EDTA, 10mM Tris-HCl pH
8.1), and TE buffer (1mM EDTA, 10mM Tris-HCl pH 8.0). After proteinase
K digestion and turbo DNase I (4U per sample) treatment, the RNA was recovered
by acidic phenol/chloroform extraction and ethanol precipitation.
RNA-Seq. RNA-sequencing was performed on the Illumina HiSeq2500 using the
sequencing reagents and ﬂow cells providing up to 300Gb of sequence information
per ﬂow cell. Brieﬂy, the quality of the total RNA was assessed using the Agilent
2100 Bioanalyzer. For mRNA-seq, 2 rounds of polyAþ selection was performed.
For RIP-seq including the input RNA-seq, no polyAþ or other selection was
performed, followed by conversion to cDNAs. We used the stranded mRNA library
generation kits per manufacturer’s instructions (Agilent, Santa Clara, CA). Library
construction consists of random fragmentation of the RNA, followed by cDNA
production using random primers with inclusion of actinomycin D in the ﬁrst-
strand reaction. The ends of the cDNA are repaired, A-tailed and adaptors ligated
for indexing (four different barcodes per lane) during the sequencing runs. The
cDNA libraries were quantitated using qPCR in a Roche LightCycler 480 with the
Kapa Biosystems kit for library quantitation (Kapa Biosystems, Woburn, MA)
before cluster generation. Clusters were generated to yieldB725–825K clusters per
mm2. Cluster density and quality were determined during the run after the ﬁrst
base addition parameters were assessed. We ran paired end 2 50 bp sequencing
runs to align the cDNA sequences to the reference genome.
Bioinformatic analyses. We obtained 35–55 million of paired 51 bp reads for each
sample. The investigator was blinded to sample identities when performing
bioinformatic analyses. All the reads were mapped to the human reference genome
(GRCh37/hg19) using TopHat (v2.0.13) with a gene transfer ﬁle (GTF version
GRCh37.70). Low quality mapped reads (MQ430) were removed from the ana-
lysis. The mean insert sizes and the s.d.’s were calculated using Picard-tools
(v1.126) (http://broadinstitute.github.io/picard/).
For mRNA-Seq, read count tables were generated using HTSeq (v0.6.0)53 and
deferential expression (DE) analysis of genes were performed using DESeq (v3.0)54.
Deferential exon usage was performed using DEXSeq (v3.1)29. Two independent
biological repeats for control and KD were included in both DEseq and DEXseq.
For 293 cells, the mRNA-seq results of the control samples include (1) those from
the doxycycline-treated parental Flp-In T-REx 293 cells by us and (2) those from
the doxycycline-treated control Flp-In T-REx 293 cells performed by another
group unrelated to us (sample GSM1095127 in GSE44976)31, and the two AKAP95
KD samples were from the two different clones (miR#8 and miR#12) of Flp-In
T-REx 293 cells stably expressing AKAP95 microRNAs after doxycycline
treatment. For mouse ES cells, the two biological repeats for both control
and shRNA#1-mediated Akap95 KD were independently generated by two
different persons in our lab. The read per million normalized BigWig ﬁles were
generated using BEDTools (v2.17.0)55 and bedGraphToBigWig tool (v4). All the
downstream statistical analyses and generating plots were performed in R (v3.1.1)
(http://www.r-project.org/). Gene ontology analysis was performed at DAVID
(http://david.ncifcrf.gov/).
For RIP-Seq, mapped ﬁles were passed to Model-based Analysis of ChIP-Seq
(MACS) (v1.4.2 20120305)56 for peak calling and HOMER (vv3.12, 6-8-2012)
(http://homer.salk.edu/homer/)57 was used for Motif ﬁnding. Bedgraph ﬁles
generated by MACS were then normalized based on read per million and converted
to BigWig ﬁles using bedGraphToBigWig. The input RNA-seq ﬁles were not
subject to MACS. The genomic regions for annotation (intergenic regions, exons,
UTRs, distal and proximal introns) were extracted from the GTF ﬁle used above.
Peak annotations and coverage calculations for these genomic regions were
performed using Bedtools and SAMtools (v0.1.18)58, respectively. Proﬁle plots were
generated by ngs.plot (v2.47)59.
Statistics. All data are shown as mean values with s.d. Unless otherwise speciﬁed
in ﬁgure legends, the unpaired two-tailed Student’s t-test was used under the
assumption of Gaussian (normal) distribution to calculate P values and evaluate the
statistical signiﬁcance of the difference between the indicated samples as described
in ﬁgure legends, and the variances are similar between the groups being statisti-
cally compared.
Data availability. The RIP-seq an RNA-seq data have been deposited in the Gene
Expression Omnibus database, with accession code GSE81916. All other data is
available from the author upon reasonable request.
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